Pilot Trial of Orencia in Myasthenia Gravis Patients Inadequately Responsive to Conventional Immunotherapy
试验速览
- 阶段
- 早期 1 期
- 状态
- 终止
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- Subjective Composite Score of Myasthenia Gravis (MG) Severity
研究概览
简要总结
This pilot research study is being done to see if the drug abatacept (Orencia ®) will be helpful in treating patients with myasthenia gravis (MG) who do not respond satisfactorily to other drugs that are used to suppress the immune system. Abatacept has been successful in treating experimental MG in laboratory animals, and this study is to determine its effectiveness in patients with MG.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 85 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Able to comprehend and willing to sign an Informed Consent Form (ICF)
- •Male or female 16 to 85 years of age
- •Diagnosis of DEFINITE Myasthenia Gravis
- •History of inadequate response to conventional MG treatment
- •Clinical laboratory findings within the normal range or, if outside the normal range, deemed not clinically significant by the Investigator
- •Female patients of childbearing potential who are not be breastfeeding, have a negative pregnancy test, have no intention to become pregnant during the course of the study, and are using contraceptive drugs or devices to prevent pregnancy during their participation in the study
- •Willing to cooperate with study requirements, including visits to the study site every 2 months.
排除标准
- •Subject's MG is responding adequately to conventional immunosuppressive treatment
- •Subject has had no previous trial of other immunosuppressive agents
- •Subject has a history of Chronic Obstructive Pulmonary Disease (COPD)
- •Subject is impaired, incapacitated or incapable of completing study-related assessments
- •Subject has the presence at screening of any severe, progressive or uncontrolled renal, hepatic, hematologic, gastrointestinal, pulmonary, cardiac, neurologic or cerebral disease, whether or not related to MG that, in the opinion of the Investigator, might place the subject at unacceptable risk for participation in the study.
- •Female subject has a history of breast cancer screening that is suspicious for malignancy and in whom the possibility of malignancy cannot be reasonably excluded by additional clinical, laboratory or other diagnostic evaluations
- •Subject has a history of cancer in the last 5 years, other than non-melanoma skin cell cancers cured by local resection or carcinoma in situ
- •Subject currently abuses drugs or alcohol
- •Subject has evidence of active or latent bacterial or viral infections, including positive infectious disease laboratory test result (Hepatitis B, Hepatitis C or HIV)
- •Subject has history of herpes zoster or cytomegalovirus (CMV) infection that resolved less than 2 months prior to screening visit
- •Subject has received any live vaccine within 3 months of screening
- •Subject has a history of serious bacterial infection within in the last 3 months, unless treated and resolved with antibiotics; or, any chronic bacterial infection
- •Subject is at risk for tuberculosis
- •Subject has any of the following laboratory values: Hemoglobin < 8.5 g/dL; White Blood Cells (WBC) < 3000 mm3; Platelets < 100,000 mm3; Serum creatinine > 2x upper limit of normal (ULN); Serum Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) > 2x ULN
- •Subject is unable or unwilling to maintain weekly injection schedule
- •Subject has undergone a change in immunosuppressive medications within the last three months prior to enrollment.
- •Subject has neurological impairment due to a condition other than MG, including history of transient ischemic attack within the past year
- •Subject has taken any investigational study drug within 28 days or five half-lives of the prior agent, whichever is greater, prior to dosing
- •Subject has had previous exposure to Orencia (abatacept)
- •Subject is a prisoner or is involuntarily incarcerated
- •Subject is compulsorily detained for treatment of either psychiatric or physical illness
- •Subject is judged to be actively suicidal or a suicide risk by the Investigator
研究组 & 干预措施
Abatacept
125mg abatacept in 1ml solution administered once per week by subcutaneous injection
干预措施: Abatacept Injection (Drug)
结局指标
主要结局
Subjective Composite Score of Myasthenia Gravis (MG) Severity
时间窗: 12 months
The "Subjective Score of MG Severity" is a composite score of subjective measurements of MG severity as designed by Dr. Daniel Drachman. The investigator will rate each subjective measure on a scale of 0 (no impairment) to 3 (severe impairment). The composite score of these measurements determined at baseline and at two-month increments through 12 months. The domains that make up the subjective score are: Diplopia, Ptosis, Arm strength, Leg strength, Speech, Voice, Chewing, Swallowing, Respiration, and General Health Status. The change in the composite subjective score at 12 months as compared to baseline is one of the primary outcomes. Patients that show an improvement in MG symptoms should have a lower score at 12 months as compared to baseline.
Objective Composite Score of Myasthenia Gravis (MG) Severity
时间窗: 12 months
The "Objective Score of MG Severity" is a composite score of subjective measurements of MG severity as designed by Dr. Daniel Drachman. The investigator will score each objective measure on a scale of 0 (no impairment) to 3 (severe impairment). The composite score of these measurements determined at baseline and at two-month increments through 12 months. The domains that make up the objective score are: Diplopia, Ptosis, Arm abduction, Gait, Orbicularis Oculi, Orbicularis Oris, Tongue, Slurp Test. The change in the composite objective score at 12 months as compared to baseline is one of the primary outcomes. Patients that show an improvement in MG symptoms should have a lower score at 12 months as compared to baseline.
Muscle Strength (Dynamometry)
时间窗: 12 months
Muscle strength in 11 muscle groups will be measured by hand-held dynamometry at baseline and at two-month increments through 12 months. The change in muscle strength (in pounds) at 12 months as compared to baseline is one of the primary outcomes. Patients that show an improvement in MG symptoms should show increased muscle strength at 12 months as compared to baseline.
次要结局
- Acetylcholine Receptor (AChR) or Muscle-Specific Kinase (MuSK) Antibody Concentrations(12 months)
- Myasthenia Gravis Composite Score (MGC)(12 months)
- Myasthenia Gravis Quality of Life-15 (MG QOL15) Score(12 months)